HGH Fragment 176-191 Peptide (AOD 9604) – Research Grade
Product Overview
HGH frag 176 191 (also known as AOD 9604) is a synthetic 16-amino acid peptide fragment derived from the C-terminal region of human growth hormone (hGH), corresponding to amino acid residues 176–191 . This peptide was developed by Metabolic Pharmaceuticals in the late 1990s as a research tool to isolate and study the lipolytic (fat breakdown) properties of growth hormone while minimizing effects on insulin sensitivity and IGF-1 levels.
The peptide’s structure incorporates an additional tyrosine residue at the N-terminus, a modification theorized to support stability and activity . Unlike full-length growth hormone, HGH frag 176 191 is hypothesized to selectively target pathways involved in lipid metabolism without significantly impacting insulin or IGF-1 levels .
⚠️ Research Context: This peptide is listed on the World Anti-Doping Agency (WADA) Prohibited List (Section S2.2) and is not FDA-approved for human use . It is intended exclusively for laboratory research purposes.

Mechanism of Action
HGH frag 176 191 functions through pathways distinct from full-length growth hormone :
-
Lipolysis Stimulation: Promotes the breakdown of stored fat (triglycerides) into free fatty acids
-
Lipogenesis Inhibition: Reduces the formation of new fat deposits
-
Receptor Independence: Does not activate GH receptors, minimizing endocrine effects
-
Fat Oxidation Enhancement: Increases lipid oxidation without stimulating IGF-1 or GH signaling
Key Research Applications:
-
Adipose tissue metabolism and fat oxidation studies
-
Lipid profile and metabolic regulation research
-
Cartilage regeneration and tissue repair studies
-
Obesity and metabolic syndrome pathway investigations
Product Specifications
| Parameter | Specification |
|---|---|
| Product Name | HGH Fragment 176-191 (AOD 9604) |
| Synonyms | AOD 9604, hGH (176-191), Human Growth Hormone (176-191) |
| CAS Number | 66004-57-7 |
| Molecular Formula | C₇₈H₁₂₃N₂₃O₂₃S₂ |
| Molecular Weight | ~1815.1 g/mol |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Disulfide bridge: Cys7-Cys14) |
| Sequence Short | YLRIVQCRSVEGSCGF (Disulfide bridge: Cys7-Cys14) |
| Length | 16 Amino Acids |
| Purity | ≥99% (HPLC Verified) |
| Form | White to off-white lyophilized powder |
| Endotoxin Level | <0.25 EU/mg |
| Storage | -20°C (long-term); 2-8°C (short-term), protected from light and moisture |
Quality Assurance
Every batch of HGH frag 176 191 undergoes rigorous analytical testing to ensure maximum purity and research integrity:
| Test | Method | Specification |
|---|---|---|
| Identity | ESI-MS | Matches theoretical mass (1815.09 Da) |
| Purity | RP-HPLC | ≥99% area |
| Sequence Confirmation | MS/MS | 100% sequence coverage |
| Disulfide Bridge | Confirmed | Cys7-Cys14 formation |
| Endotoxin | LAL Test | <0.25 EU/mg |
Certificate of Analysis (COA) available upon request.

Research Background
Development History
HGH frag 176 191 was originally developed by Metabolic Pharmaceuticals in the late 1990s for obesity research . However, it “did not show a clinically meaningful weight loss outcome across the trial population” . The peptide has since been studied in various research contexts including lipid metabolism, cartilage repair, and tissue regeneration .
Preclinical Research
| Research Area | Findings |
|---|---|
| Lipid Metabolism | Decreases body weight and adipose tissue mass in research models |
| Cartilage Regeneration | Enhances cartilage regeneration in knee osteoarthritis models |
| Cancer Research | Binds to Ki-67 and estrogen receptor; enhances toxicity of doxorubicin-loaded nanoparticles to breast cancer cells |
Clinical & Regulatory Status
-
FDA Status: Not approved for human use; Category 2 bulk drug substance
-
WADA Status: Prohibited (Section S2.2)
-
Research Use: Sold online only as a research chemical; not authorized for clinical treatment
-
Clinical Trials: Limited data; no clinically meaningful weight loss outcome demonstrated in trial populations
Storage & Reconstitution Guidelines
Storage Conditions:
-
Lyophilized (Long-term): -20°C, protected from light and moisture
-
Lyophilized (Short-term): 2°C – 8°C (refrigerated)
-
Reconstituted: 4°C for up to 7 days; aliquot and store at -20°C for longer storage; avoid repeated freeze-thaw cycles
Reconstitution Protocol:
-
Allow vial to reach room temperature
-
Add sterile bacteriostatic water or 0.9% sodium chloride solution
-
Gently swirl (do not vortex) until fully dissolved
-
For long-term storage, aliquot to minimize freeze-thaw degradation
Note: Peptides are sensitive to formulation, process, and environmental conditions that may lead to aggregation and degradation.
Important Notice
⚠️ FOR RESEARCH USE ONLY
This product is not intended for human consumption, diagnostic use, therapeutic application, or clinical administration. HGH Fragment 176-191 is a research chemical intended exclusively for in-vitro and laboratory research purposes.
-
Not approved by the FDA for human use
-
Not a dietary supplement, food additive, or pharmaceutical
-
Listed on the WADA Prohibited List (Section S2.2)
-
Intended solely for qualified researchers and scientific institutions
By purchasing this product, you confirm that you are a licensed researcher or laboratory professional and agree to use this compound in compliance with all applicable local, national, and international regulations.
Why Choose PeptidesUnit.com?
| Feature | Benefit |
|---|---|
| ✅ Premium Purity | ≥99% HPLC-verified purity guaranteed |
| ✅ Research-Grade Quality | Manufactured under GMP-aligned conditions |
| ✅ Third-Party Tested | Independent COA for every batch |
| ✅ Secure Packaging | Lyophilized in amber glass vials with tamper-evident seals |
| ✅ Fast Global Shipping | Discreet packaging with real-time tracking |
| ✅ Competitive Pricing | Direct-from-manufacturer pricing |
Order Now
HGH frag 176 191 (AOD 9604) Peptide 5mg – ≥99% Purity
Available for immediate shipment





Reviews
There are no reviews yet